Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Ralley E Prentice und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Immunity, Innate, Adaptive Immunity, Inflammatory Bowel Diseases, Pregnancy Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Monash University RTP scholarship, National Health and Medical Research Council Postgraduate Scholarship, Crohn's Colitis Australia Postgraduate Scholarship.
Abstract (Originalsprache)
Background and Aims Inflammatory bowel disease (IBD) therapeutics and pregnancy itself are known to impact immune cell populations, but a detailed understanding of the effect of specific therapies is lacking, particularly for infants exposed in utero. With comprehensive flow cytometric assessment, we aimed to explore how IBD and its treatment impact both maternal and infant immunophenotypes and cytokine production.
Methods
Peripheral blood was taken for flow cytometry immunophenotyping and quantification of cytokine responses to stimulation from women with IBD and healthy controls throughout pregnancy, at delivery, and postpartum. Blood samples were also taken from the umbilical cord and peripherally from the resultant offspring at the age of 6 weeks.
Results
Eighteen participants (16 with IBD and 2 healthy controls) were recruited to this single-center prospective cohort study. Basal T regulatory cell population proportions were 46% lower (0.21% vs 0.39%, P = .027) in those participants exposed to ustekinumab (n = 4). No other significant differences were noted in immunophenotype according to drug therapy exposure. Basal (1.75% vs 0.47%, P = .036) and lipopolysaccharide-stimulated (72.2% vs 64.7%, P = .028) production of tumour necrosis factor by classical dendritic cells were increased 3.7- and 1.1-fold, respectively, in those with an elevated fecal calprotectin (n = 6). Basal CD4+α4β7+ (41.4% to 66.5%, P = .0043) and CD8+α4β7+ (81.2% to 93.6%, P = .007) population proportions increased 1.6- and 1.2-fold, respectively, in infants from birth to 6 weeks.
Conclusions
This study provides the foundation for ongoing investigation to more definitively extricate the impact of maternal IBD activity, drug exposures, and disease phenotype on infant immune system development and function. These novel data suggest that IBD pharmacotherapies may not significantly impact maternal or infant immune regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
- Department of Gastroenterology, Monash Health, Melbourne, VIC, Australia.
- Department of Medicine, Monash University, Melbourne, VIC, Australia.
- The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
- Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
- Department of Paediatrics, Monash University, Melbourne, VIC, Australia.
ORCID-Profile: Ralley E Prentice, Emma Flanagan
Förderung
- Monash University RTP scholarship
- National Health and Medical Research Council Postgraduate Scholarship
- Crohn's Colitis Australia Postgraduate Scholarship
- the National Health and Medical Research Council Investigator Grant Leadership 1
- Fielding Foundation's Innovation Award and Fellowship
- Crohn’s Colitis Australia Postgraduate Scholarship
- Fielding Foundation’s Innovation Award and Fellowship
Zitieren
APA
Prentice, R. E., Cho, S. X., Bell, S. J., Nold-Petry, C. A., Lee, M., Zorkau, I., Burns, M., Wright, E. K., Flanagan, E., Nold, M. F., & Goldberg, R. (2025). Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf052
Vancouver
Prentice RE, Cho SX, Bell SJ, Nold-Petry CA, Lee M, Zorkau I, et al. Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf052
BibTeX
@article{Prentice2025,
author = {Prentice, Ralley E and Cho, Steven X and Bell, Sally J and Nold-Petry, Claudia A and Lee, Marie and Zorkau, Indiana and Burns, Megan and Wright, Emily K and Flanagan, Emma and Nold, Marcel F and Goldberg, Rimma},
title = {Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf052}
}
EUVIMED